Nature Medicine, Published online: 07 June 2026; doi:10.1038/s41591-026-04479-3 As presented at the American Diabetes Association Meeting, in this phase 3 trial, weekly subcutaneous injections of survodutide, a glucagon receptor/GLP-1R dual agonist, lowered liver fat content and body weight compared to placebo in adults with obesity and at-risk metabolic dysfunction-associated steatotic liver disease (MASLD).
Nature Medicine, Published online: 07 June 2026;
doi:10.1038/s41591-026-04479-3
As presented at the American Diabetes Association Meeting, in this phase 3 trial, weekly subcutaneous injections of survodutide, a glucagon receptor/GLP-1R dual agonist, lowered liver fat content and body weight compared to placebo in adults with obesity and at-risk metabolic dysfunction-associated steatotic liver disease (MASLD).
— Source: Nature Medicine (https://www.nature.com/articles/s41591-026-04479-3)